Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?
Ramon-Patino JL, Ruz-Caracuel I, Heredia-Soto V, Garcia de la Calle LE, Zagidullin B, Wang Y, Berjon A, Lopez-Janeiro A, Miguel M, Escudero J, Gallego A, Castelo B, Yebenes L, Hernandez A, Feliu J, Pelaez-García A, Tang J, Hardisson D, Mendiola M, Redondo A. Ramon-Patino JL, et al. Among authors: castelo b. Cancers (Basel). 2022 Feb 12;14(4):912. doi: 10.3390/cancers14040912. Cancers (Basel). 2022. PMID: 35205661 Free PMC article.
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.
Mendiola M, Martínez-Marin V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto Á, Miguel M, Díaz E, Gámez A, Fresno JÁ, Ramírez de Molina A, Hardisson D, Espinosa E, Redondo A. Mendiola M, et al. Among authors: castelo b. Oncotarget. 2016 Apr 26;7(17):24217-27. doi: 10.18632/oncotarget.8128. Oncotarget. 2016. PMID: 26992213 Free PMC article.
Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M, Redondo A, Heredia-Soto V, Herranz J, Berjón A, Hernández A, Miguel-Martín M, Crespo R, Barriuso J, Cruz P, Yébenes L, Peláez-García A, Castelo B, DE Molina AR, Feliu J, Hardisson D. Mendiola M, et al. Among authors: castelo b. Anticancer Res. 2018 Sep;38(9):5393-5400. doi: 10.21873/anticanres.12869. Anticancer Res. 2018. PMID: 30194194
Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience.
Gutierrez-Sainz L, Martinez-Marin V, Viñal D, Martinez-Perez D, Pedregosa J, Garcia-Cuesta JA, Villamayor J, Zamora P, Pinto A, Redondo A, Castelo B, Cruz P, Higuera O, Custodio A, Gallego A, Sanchez-Cabrero D, de Castro-Carpeño J, Espinosa E, Feliu J. Gutierrez-Sainz L, et al. Among authors: castelo b. Clin Transl Oncol. 2021 Jun;23(6):1245-1252. doi: 10.1007/s12094-020-02515-3. Epub 2020 Nov 24. Clin Transl Oncol. 2021. PMID: 33231859
Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A, Redondo A, Zamora P, Castelo B, Espinosa E. Pinto A, et al. Among authors: castelo b. Anticancer Drugs. 2010 Nov;21(10):890-6. doi: 10.1097/CAD.0b013e32833e83b2. Anticancer Drugs. 2010. PMID: 20729712 Review.
48 results